Neoadyavant therapy of non-small cell lung cancer: are there any perspectives?


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The main method of treatment of patients with the initial stages of lung cancer is a radical surgical intervention, which can be supplemented by various types of conservative treatment. Despite the demonstrated advantages, neoadjuvant chemotherapy can not yet be considered as a standard in the treatment of primary operable non-small cell lung cancer (NSCLC). The use of targeted and immune drugs may become an alternative to cytotoxic drugs and should be evaluated in large studies. The present article reflects the state of the problem of neoadjuvant drug therapy of NSCLC and shows promising directions of treatment using modern antitumor drugs.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Yu. Ragulin

Medical Radiological Research Center n.a. A.F. Tsyba - a Branch of FSBI “National Medical Research Radiological Center" of RMH

Email: yuri.ragulin@mail.ru

Әдебиет тізімі

  1. Состояние онкологической помощи населению России в 2015 году/ Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016. 236 с.
  2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016;66:7.
  3. Болотина Л.В., Пикин О.В., Королева Л.А., Дешкина Т. И. Опыт комбинированного лечения больных местнораспространенным немелкоклеточным раком легкого. Онкология. Журнал им. П.А. Герцена. 2013;1(5):32-5.
  4. Миллер С.В., Тузиков С.А., Завьялов А.А. и др. Анализ осложнений комбинированного лечения немелкоклеточного рака легкого. Сибирский онкологический журнал. 2007;4:50-6.
  5. Felip E., Rosell R., Maestre J.A., Rodriguez-Paniagua J.M., Moran T., Astudillo J., Alonso G., Borro J.M., Gonzalez-Larriba J.L., Torres A., Camps C., Guijarro R., Isla D., Aguilo R., Alberola V., Padilla J., Sanchez-Palencia A., Sanchez J.J., Hermosilla E., Massuti B.; The Spanish Lung Cancer Group. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J. Clin. Oncol. 2010;28:3138-45.
  6. Pisters K.M., Vallières E., Crowley J.J., Franklin W.A., Bunn P.A.Jr, Ginsberg R.J., Putnam J.B. Jr, Chansky K., Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J. Clin. Oncol. 2010;28:1843-49.
  7. Gilligan D., Nicolson. M., Smith I., Groen H., Dalesio O., Goldstraw P., Hatton M., Hopwood P., Manegold C., Schramel F., Smit H., van Meerbeeck J., Nankivell M., Parmar M., Pugh C., Stephens R. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/ EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007;369:1929-37.
  8. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non- small-cell lung cancer: a systematic review and metaanalysis of individual participant data. Lancet. 2014;383:1561-71.
  9. Burdett S., Pignon J.P., Tierney J. Adjuvant chemotherapy for resected early-stage nonsmall cell lung cancer. Cochrane Database Syst. Rev. 2015;3:CD011430.
  10. NSCLC Meta-analyses Collaborative Group, Arriagada R., Auperin A., Burdett S., Higgins J.P, Johnson DH, Le Chevalier T., Le Pechoux C, Parmar M.K., Pignon J.P, Souha-mi R.L., Stephens R.J., Stewart L.A., TierneyJ.F., Tribodet H., van Meerbeeck J. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375: 1267-77.
  11. Scagliotti G., Pastorino U., Vansteenkiste J., Spaggiari L., Facciolo F., Orlowski T.M., Maiorino L., Hetzel M., Leschinger M., Visseren-Grul C., Torri V Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J. Clin. Oncol. 2012;30(2):172-78.
  12. Lorent N., De Leyn P., Lievens Y., Verbeken E., Nackaerts K., Dooms C., Van Raemdonck D., Anrys B., Vansteenkiste J.; Leuven Lung Cancer Group: Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: Analysis of a 7-year prospective experience. Ann. Oncol. 2004;15: 1645-53.
  13. Hu X.F., Duan L., Jiang G.N., Chen C., Fei K.E. Surgery following neoadjuvant chemotherapy for non-small-cell lung cancer patients with unexpected persistent pathological N2 disease. Mol. Clin. Oncol. 2016;4(2): 261-67.
  14. Felip E., Rosell R., Maestre J.A., Rodrfguez-Paniagua J.M., Moran T., Astudillo J., Alonso G., Borro J.M., Gonzalez-Larriba J.L., Torres A., Camps C., Guijarro R., Isla D., Aguiló R., Alberola V., Padilla J., Sanchez-Palencia A., Sanchez J.J., Hermosilla E., Massuti B.; Spanish Lung Cancer Group. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early- stage non-small-cell lung cancer. J. Clin. Oncol. 2010;28:3138-45.
  15. Foote M. The Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice? Oncologist. 1998;3(5):365-68.
  16. Полищук Т.В. Оценка качества жизни как критерий эффективности комбинированного лечения больных немелкоклеточным раком легкого III стадии. Дисс. канд. мед. наук. Томск, 2008. 151 с.
  17. Wu Y.L., Yang X.N., Zhong W., et al. Multicentre randomized controlled study comparing adjuvant vs neo-adjuvant chemotherapy with docetaxel plus carboplatin in resectable stage IB to IIIA NSCLC: final results of CSLC0501. Ann. Oncol. 2016;27(suppl 6):11780.
  18. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., Mitsudomi T. Mutations of the epidermal growth factor receptorgene in lung cancer: biological and clinical implications. Cancer Res. 2004;64:8919-23.
  19. Lara-Guerra H., Waddell T.K., Salvarrey M.A., Joshua A.M., Chung C.T., Paul N., Boerner S., Sakurada A., Ludkovski O., Ma C., Squire J., Liu G., Shepherd F.A., Tsao M.S., Leighl N.B. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J. Clin. Oncol. 2009;27:6229-36.
  20. Hishida T., Nagai K., Mitsudomi T., Yokoi K., Kondo H., Horinouchi H., Akiyama H., Nagayasu T., Tsuboi M.; Japan Clinical Oncology Group. Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. J. Thorac. Cardiovasc. Surg. 2010;140:e69-71.
  21. Schaake Е.Е., Kappers I., Codrington E., Valdés Olmos R.A., Teertstra H.J., van Pel R., Burgers J.A., van Tinteren H., Klomp H.M. Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2012;30(22):2731-38.
  22. Marech I., Vacca A., Gnoni A., Silvestris N., Lorusso V. Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature. Tumori. 2013;99(5):241-44.
  23. Рыбас А.Н., Левченко Е.В., Рыбас А.В. Прогнозирование эффекта неоадъювантной химиотерапии у больных немелкоклеточным раком легкого III стадии на этапах комбинированного лечения. Вопросы онкологии. 2016;62(4):499-503.
  24. Friboulet L., Olaussen K.A., Pignon J.P., Shepherd F.A., Tsao M.S., Graziano S., Kratzke R., Douillard J.Y., Seymour L., Pirker R., Filipits M., André F., Solary E., Ponsonnailles F., Robin A., Stoclin A., Dorvault N., Commo F., Adam J., Vanhecke E., Saulnier P., Thomale J., Le Chevalier T., Dunant A., Rousseau V., Le Teuff G., Brambilla E., Soria J.C. ERCC1 isoform expression and DNA repair in nonsmall-cell lung cancer. N. Engl. J. Med. 2013; 368:1101-10.
  25. Zhu C.Q., Tsao M.S. Prognostic markers in lung cancer: is it ready for prime time? Transl. Lung Cancer Res. 2014;3(3):149-58.
  26. Forde P.M., Smith K.N., Chaft J.E., et al. Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. Ann. Oncol. 2016;27(6):1-36.
  27. Owen D., Bunn P Jr, Johnson B., et al. Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol. 2017;12(1 Suppl):S1082.
  28. https://clinicaltrials.gov/ct2/show/ NCT02716038
  29. https://clinicaltrials.gov/ct2/show/NCT02 938624?term=Neoadjuvant+in+NSCLC&ra nk=14

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2017

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>